BioRestorative Therapies Holds Shareholder Vote
Ticker: BRTX · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1505497
| Field | Detail |
|---|---|
| Company | Biorestorative Therapies, INC. (BRTX) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: BRTX
TL;DR
BRTX held a shareholder vote on Sept 19th, details filed today.
AI Summary
BioRestorative Therapies, Inc. filed an 8-K on September 23, 2024, reporting on a matter submitted to a vote of its security holders on September 19, 2024. The filing details the company's operations and corporate structure, including its principal executive offices located at 40 Marcus Drive, Melville, NY.
Why It Matters
This filing indicates a significant corporate event requiring shareholder approval, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: medium — Shareholder votes can signal significant corporate changes or disagreements, introducing uncertainty.
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — Registrant
- September 19, 2024 (date) — Date of earliest event reported
- September 23, 2024 (date) — Date of report
- 40 Marcus Drive, Melville, New York 11747 (location) — Principal executive offices
FAQ
What specific matter was submitted for a vote by BioRestorative Therapies, Inc. security holders?
The filing indicates that a matter was submitted to a vote of security holders, but the specific details of the matter are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 19, 2024.
What is the principal executive office address for BioRestorative Therapies, Inc.?
The principal executive offices are located at 40 Marcus Drive, Melville, New York 11747.
What is the trading symbol and exchange for BioRestorative Therapies, Inc. securities?
The filing mentions that securities are registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, but the specific trading symbol and exchange are not listed in the provided excerpt.
Has BioRestorative Therapies, Inc. had a former name or address change?
Yes, the company was formerly known as Stem Cell Assurance, Inc., with a date of name change on November 10, 2010.
Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2024-09-23 16:33:16
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value BRTX NASDAQ Capital Marke
Filing Documents
- brt8k91924.htm (8-K) — 30KB
- 0001021771-24-000180.txt ( ) — 162KB
- brtx-20240919.xsd (EX-101.SCH) — 4KB
- brtx-20240919_lab.xml (EX-101.LAB) — 21KB
- brtx-20240919_pre.xml (EX-101.PRE) — 16KB
- brt8k91924_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On September 19, 2024, BioRestorative Therapies, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders: (i) elected the nominee as the Class I director, (ii) approved an amendment to the Company's 2021 Stock Incentive Plan (the "Plan") to increase the number of shares of common stock authorized to be issued pursuant to the Plan from 3,850,000 to 6,850,000, and (iii) ratified the selection of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The following is a listing of the votes cast for or withheld, and the number of broker non-votes, with respect to the nominee for Class I director and a listing of the votes cast for and against, as well as abstentions and broker non-votes, with respect to the other matters voted upon at the Annual Meeting, as applicable. 1. Election of Class I Director: Number of Shares For Withheld Broker Non-Votes Nickolay Kukekov, Ph.D 2,050,111 135,114 2 , 048 , 738 2. Approval of amendment to the Company's 2021 Stock Incentive Plan: For 1,647,022 Against 518,921 Abstentions 19,282 Broker Non-Votes 2 , 048 , 738 3. Ratification of the selection of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: For 4,152,145 Against 18,696 Abstentions 63,122
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIORESTORATIVE THERAPIES, INC. Dated: September 23, 2024 By: /s/ Lance Alstodt Lance Alstodt President and CEO